Use of artificial networks in clinical trials: a pilot study to predict responsiveness to donepezil in Alzheimer's disease

J Am Geriatr Soc. 2002 Nov;50(11):1857-60. doi: 10.1046/j.1532-5415.2002.50516.x.

Abstract

Objectives: To evaluate the accuracy of artificial neural networks compared with discriminant analysis in classifying positive and negative response to the cholinesterase inhibitor donepezil in a group of Alzheimer's disease (AD) patients.

Design: Convenience sample.

Setting: Patients with mild to moderate AD consecutively admitted to a geriatric day hospital and treated with donepezil 5 mg/day.

Participants: Sixty-one older patients of both sexes with AD.

Measurements: Accuracy in detecting subjects sensitive (responders) or not (nonresponders) to 3-month therapy with ANNs. The criterion standard for evaluation of efficacy was the scores of Alzheimer's Disease Assessment Scale-Cognitive portion and Clinician's Interview Based Impression of Change-plus scales.

Results: ANNs were more effective in discriminating between responders and nonresponders than other advanced statistical methods, particularly linear discriminant analysis. The total accuracy in predicting the outcome was 92.59%.

Conclusions: ANNs appear to be a useful tool in detecting patient responsiveness to pharmacological treatment in AD.

Publication types

  • Comparative Study
  • Validation Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / drug therapy*
  • Cholinesterase Inhibitors / administration & dosage
  • Cholinesterase Inhibitors / therapeutic use*
  • Clinical Trials as Topic*
  • Discriminant Analysis*
  • Donepezil
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Indans / administration & dosage
  • Indans / therapeutic use*
  • Male
  • Middle Aged
  • Neural Networks, Computer*
  • Pilot Projects
  • Piperidines / administration & dosage
  • Piperidines / therapeutic use*
  • Predictive Value of Tests
  • Reproducibility of Results
  • Severity of Illness Index

Substances

  • Cholinesterase Inhibitors
  • Indans
  • Piperidines
  • Donepezil